Go to the list of all blogs
Allana's Avatar
published in Blogs
Feb 20, 2023
Mosaic Company (MOS, $49.85) comparisons of last two quarters of earnings

Mosaic Company (MOS, $49.85) comparisons of last two quarters of earnings

A distributor and producer of fertilizer, Mosaic Company just released its earnings for the previous two quarters. The company published its Q3 earnings on November 2, 2022, and its Q4 profits on February 7, 2023.

In Q3 2022, Mosaic Company reported net sales of $2.4 billion, an increase of 4% compared to the same period in the previous year. Gross margin increased by 2 percentage points to 17%, while adjusted earnings per share (EPS) were $0.43, up from $0.17 in Q3 2021. The company's phosphate segment saw higher sales volumes and prices, which drove the overall sales growth.

Moving on to Q4 2022, Mosaic Company recorded net revenues of $2.6 billion, up 8% from the same quarter the year prior. Adjusted EPS grew from $0.35 in Q4 2021 to $0.58, a 4 percentage point improvement in adjusted gross margin to 20%. While the phosphate portion of the corporation continued to do well, the potash segment witnessed increasing sales volumes and pricing.

While Mosaic Company's earnings have been positive over the last two quarters, the 10-day RSI Oscillator for MOS moved out of overbought territory on February 13, 2023. This could be a sign that the stock is shifting from an upward trend to a downward trend. 

Tickeron's A.I.dvisor looked at 37 instances where the indicator moved out of the overbought zone. In 31 of the 37 cases, the stock moved lower in the days that followed. This puts the odds of a move down at 84%. 

Both net sales and gross margin increased during the most recent two quarters, according to Mosaic Company's earnings reports. The 10-day RSI Oscillator's recent rise out of overbought area, however, should alert traders that the stock may be transitioning to a bearish trend. Before making any trading decisions, traders may want to take into account this information and the analysis provided by Tickeron's A.I.dvisor.
 

Related Ticker: MOS

Contributor

Allana's AvatarAllana|Expert

Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.


Momentum Indicator for MOS turns positive, indicating new upward trend

MOS saw its Momentum Indicator move above the 0 level on August 04, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 83 similar instances where the indicator turned positive. In of the 83 cases, the stock moved higher in the following days. The odds of a move higher are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for MOS just turned positive on August 04, 2026. Looking at past instances where MOS's MACD turned positive, the stock continued to rise in of 50 cases over the following month. The odds of a continued upward trend are .

MOS moved above its 50-day moving average on August 04, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for MOS crossed bullishly above the 50-day moving average on July 22, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where MOS advanced for three days, in of 304 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 239 cases where MOS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where MOS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

MOS broke above its upper Bollinger Band on August 05, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.651) is normal, around the industry mean (1.315). MOS has a moderately high P/E Ratio (167.214) as compared to the industry average of (47.338). MOS's Projected Growth (PEG Ratio) (2.020) is slightly higher than the industry average of (1.480). Dividend Yield (0.038) settles around the average of (0.043) among similar stocks. P/S Ratio (0.610) is also within normal values, averaging (1.423).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. MOS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MOS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 82, placing this stock worse than average.

Notable companies

The most notable companies in this group are CF Industries Holding (NYSE:CF), Mosaic Company (The) (NYSE:MOS).

Industry description

The agricultural chemicals sector includes companies that produce chemical products for the agricultural industry applications like crop protection, animal health, biotechnology and pharmaceutical-related products. Some of the largest agricultural chemicals producers include Nutrien Ltd., Corteva Inc., and FMC Corporation.

Market Cap

The average market capitalization across the Chemicals: Agricultural Industry is 9.4B. The market cap for tickers in the group ranges from 14.68K to 51.02B. CTVA holds the highest valuation in this group at 51.02B. The lowest valued company is CGSI at 14.68K.

High and low price notable news

The average weekly price growth across all stocks in the Chemicals: Agricultural Industry was -1%. For the same Industry, the average monthly price growth was -3%, and the average quarterly price growth was -13%. IPI experienced the highest price growth at 13%, while NXTS experienced the biggest fall at -9%.

Volume

The average weekly volume growth across all stocks in the Chemicals: Agricultural Industry was -15%. For the same stocks of the Industry, the average monthly volume growth was 49% and the average quarterly volume growth was 11%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 38
P/E Growth Rating: 65
Price Growth Rating: 59
SMR Rating: 82
Profit Risk Rating: 82
Seasonality Score: -17 (-100 ... +100)
View a ticker or compare two or three
MOS
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

a producer of phosphate and potash

Industry ChemicalsAgricultural

Profile
Details
Industry
Chemicals Agricultural
Address
101 East Kennedy Boulevard
Phone
+1 800 918-8270
Employees
14049
Web
https://www.mosaicco.com
Interact to see
Advertisement
Novo Nordisk (NVO) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $11.96 billion in revenue and $0.89 EPS, reflecting a moderation in GLP-1 growth. Eli Lilly (LLY) is expected to report around the same time, with projections of $17.87 billion in revenue and $6.99 EPS, driven by continued volume gains from Mounjaro and Zepbound.
Banco Santander (SAN) reports Q4 2025 earnings on February 4, 2026, following record nine-month attributable profit of €10.3 billion, up 11% year over year.
Uber (UBER) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $0.78 EPS and $14.32 billion in revenue, up about 20% year over year.
Qualcomm’s Q1 FY2026 report, covering the period ended December 28, 2025, arrives amid a pivotal shift in the semiconductor landscape. While handset growth moderates, the company is expanding in automotive, IoT, and AI-enabled devices.
UBS Group AG reports Q4 2025 earnings on February 4, 2026, with consensus EPS ranging $0.25–$0.67 and revenue around $11.62 billion, down YoY. HSBC Holdings plc reports Q4 earnings on February 25, 2026, with consensus EPS ~$1.57; Q3 showed resilient net interest income despite $1.4B in legal provisions.
Boston Scientific’s Q4 caps a transformative year, driven by ~15.5% organic growth from WATCHMAN, FARAPULSE electrophysiology, and MedSurg expansions. As a leader in minimally invasive devices, BSX’s results set the benchmark against Medtronic and Stryker—diversified medtech giants navigating tariffs, procedural rebounds, and innovation.
Arm, the leading provider of energy-efficient processor designs powering over 99% of smartphones and expanding into AI data centers, faces high scrutiny in Q3 FY2026 (ending Dec 31, 2025). After a strong Q2 with record royalty and licensing revenue, investors are focused on whether AI demand will continue to drive robust growth.
Datadog (DDOG) has come under pressure in recent sessions as volatility across the software sector weighs on sentiment ahead of earnings. Trading in the $108–120 range following a pullback from highs near $200, the stock reflects a disconnect between near-term market caution and resilient underlying fundamentals.
Starbucks shares have shown renewed strength in recent trading, rebounding from earlier lows within a 52-week range of $75.50 to $117.46. The recovery reflects improving comparable sales trends and a return to transaction growth, suggesting early progress from operational initiatives aimed at reconnecting with customers.
DoorDash holds a Strong Buy consensus from 33 analysts, with an average 12-month price target of $280.82, implying more than 40% upside from recent trading levels.
Amazon’s Q4 report capped a strong year marked by accelerating cloud growth, steady retail execution, and expanding advertising profitability. The results reinforced Amazon’s positioning as a core beneficiary of enterprise AI demand, particularly through AWS, while highlighting improving operating leverage across the broader business.
ConocoPhillips reported Q4 2025 adjusted EPS of $1.02, below consensus of $1.08, driven by weaker realized commodity prices.
ICE reported Q4 2025 net revenues of $2.5 billion, up 8% year-over-year, capping 20 consecutive years of record annual revenues at $9.9 billion.
Eli Lilly’s Q4 results highlight explosive growth from GLP-1 therapies, cementing leadership in obesity and diabetes. The company’s strong revenue beat and robust 2026 guidance illustrate high-growth pharma dynamics. Johnson & Johnson, in contrast, exemplifies a diversified healthcare strategy, combining pharmaceuticals, MedTech, and consumer health for steady expansion.
Eli Lilly (LLY), AbbVie (ABBV), and Merck (MRK) all reported strong Q4 2025 earnings, but the market reacted differently to each, reflecting variations in growth profiles, product concentration, and sector dynamics. AbbVie delivered Q4 revenue of $16.62 billion, up 10% year-over-year, with full-year revenue reaching $61.2 billion, an 8.6% increase. Adjusted EPS came in at $2.71, surpassing consensus, though shares dipped following the report amid ongoing Humira concerns
Novo Nordisk (NVO) reported Q4 2025 EPS of $1.02, surpassing estimates of $0.92, with revenue of $12.53B vs $11.99B expected. Full-year 2025 sales rose 10% at constant exchange rates (CER) to DKK 309B, but 2026 guidance anticipates a 5–13% decline at CER due to pricing pressures. Novartis (NVS) posted Q4 core EPS of $2.03, beating $1.99 estimates; net sales of $13.34B slightly missed consensus. FY sales grew 8%, with core EPS up 17% to $8.98.
MUFG (Mitsubishi UFJ Financial Group) posted Q3 FY2026 profits of ¥1.81 trillion, up 3.7% YoY, on track for its full-year target of ¥2.1 trillion. HSBC is set to report Q4 FY2025 earnings on Feb 25, 2026, with consensus EPS around $1.60; recent quarters showed resilient net interest income (NII) supported by Asia wealth growth.
Gogo shares continue to trade near 52-week lows around $4, weighed down by competitive threats from Starlink and slower-than-anticipated AVANCE system upgrades. William Blair downgraded the stock to Market Perform in December 2025, citing leverage concerns and intensifying rivalry in in-flight connectivity.
Quantum Computing Inc. completed a $110 million acquisition of Luminar Semiconductor on February 2, significantly strengthening its photonics and manufacturing capabilities. Shares have traded with elevated volatility, peaking near $12.70 in mid-January before retreating to the $9 range amid heavy volume.
ERII shares have remained resilient, trading near $15.47 ahead of Q4 and full-year 2025 earnings scheduled for February 25, 2026. Q3 2025 results exceeded expectations, with revenue of $32 million and EPS of $0.07, despite year-over-year declines tied to project timing.